Literature DB >> 2898211

Production of transforming growth factor-beta activity by Ki-1 positive lymphoma cells and analysis of its role in the regulation of Ki-1 positive lymphoma growth.

S R Newcom1, M E Kadin, A A Ansari.   

Abstract

The growth of activated human T lymphocytes in response to interleukin-2 (IL-2) is suppressed by transforming growth factor-beta (TGF-beta). This study presents data that show a diminished response of two human lymphoma cell lines to physiologic regulation by TGF-beta. Cell line L-428 was derived from the malignant pleural effusion of a patient with far advanced nodular sclerosing Hodgkin's disease and has been shown to have clonal gene rearrangements characteristic of both B and T lymphocytes. Cell line Mac-1 was derived from the blood of a patient with clinically indolent cutaneous T-cell lymphoma. Both cell lines express the Hodgkin's disease associated antigen, Ki-1. These Ki-1 positive lymphomas are shown to secrete TGF-beta into serum-free culture media. The addition of picogram quantities of exogenous TGF-beta to cell cultures of indolent Ki-1 lymphoma (Mac-1) suppresses IL-2-dependent mitosis; however, the suppression is less than 45%. This suppression correlates with a decrease in the number of IL-2 receptors. No inhibition of Ki-1 positive Hodgkin's cells (L-428) was observed, and proliferation dependent on polyclonal IL-2 was either not affected or was slightly potentiated by TGF-beta. Receptor analysis indicates the absence of IL-2 and TGF-beta receptors on L-428 cells. Thus, these Ki-1 lymphomas derived from activated lymphocytes appear to secrete TGF-beta activity but continue to proliferate because of defective suppression of IL-2 (and related lymphokine)-dependent DNA synthesis.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2898211      PMCID: PMC1880714     

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  25 in total

1.  A Hodgkin cell-specific antigen is expressed on a subset of auto- and alloactivated T (helper) lymphoblasts.

Authors:  R Andreesen; J Osterholz; G W Löhr; K J Bross
Journal:  Blood       Date:  1984-06       Impact factor: 22.113

2.  Purification and properties of a type beta transforming growth factor from bovine kidney.

Authors:  A B Roberts; M A Anzano; C A Meyers; J Wideman; R Blacher; Y C Pan; S Stein; S R Lehrman; J M Smith; L C Lamb
Journal:  Biochemistry       Date:  1983-12-06       Impact factor: 3.162

3.  Purification and initial characterization of a type beta transforming growth factor from human placenta.

Authors:  C A Frolik; L L Dart; C A Meyers; D M Smith; M B Sporn
Journal:  Proc Natl Acad Sci U S A       Date:  1983-06       Impact factor: 11.205

4.  Phenotypic expression of Hodgkin's and Reed-Sternberg cells in Hodgkin's disease.

Authors:  S M Hsu; K Yang; E S Jaffe
Journal:  Am J Pathol       Date:  1985-02       Impact factor: 4.307

5.  Human transforming growth factor-beta complementary DNA sequence and expression in normal and transformed cells.

Authors:  R Derynck; J A Jarrett; E Y Chen; D H Eaton; J R Bell; R K Assoian; A B Roberts; M B Sporn; D V Goeddel
Journal:  Nature       Date:  1985 Aug 22-28       Impact factor: 49.962

6.  Regulation of interleukin 2 receptor expression: effects of phorbol diester, phospholipase C, and reexposure to lectin or antigen.

Authors:  J M Depper; W J Leonard; M Krönke; P D Noguchi; R E Cunningham; T A Waldmann; W C Greene
Journal:  J Immunol       Date:  1984-12       Impact factor: 5.422

7.  Transforming growth factor-beta in human platelets. Identification of a major storage site, purification, and characterization.

Authors:  R K Assoian; A Komoriya; C A Meyers; D M Miller; M B Sporn
Journal:  J Biol Chem       Date:  1983-06-10       Impact factor: 5.157

8.  The Hodgkin's cell in nodular sclerosis does not release interleukin-1.

Authors:  S R Newcom
Journal:  J Lab Clin Med       Date:  1985-02

9.  The expression of the Hodgkin's disease associated antigen Ki-1 in reactive and neoplastic lymphoid tissue: evidence that Reed-Sternberg cells and histiocytic malignancies are derived from activated lymphoid cells.

Authors:  H Stein; D Y Mason; J Gerdes; N O'Connor; J Wainscoat; G Pallesen; K Gatter; B Falini; G Delsol; H Lemke
Journal:  Blood       Date:  1985-10       Impact factor: 22.113

10.  Production of transforming growth factor beta by human T lymphocytes and its potential role in the regulation of T cell growth.

Authors:  J H Kehrl; L M Wakefield; A B Roberts; S Jakowlew; M Alvarez-Mon; R Derynck; M B Sporn; A S Fauci
Journal:  J Exp Med       Date:  1986-05-01       Impact factor: 14.307

View more
  11 in total

1.  Interleukin-6, but not interleukin-4, is expressed by Reed-Sternberg cells in Hodgkin's disease with or without histologic features of Castleman's disease.

Authors:  S M Hsu; S S Xie; P L Hsu; J A Waldron
Journal:  Am J Pathol       Date:  1992-07       Impact factor: 4.307

2.  Expression of growth factor/receptor genes in postthymic T cell malignancies.

Authors:  I J Su; M E Kadin
Journal:  Am J Pathol       Date:  1989-09       Impact factor: 4.307

3.  Tumor necrosis factor alpha and lymphotoxin production in Hodgkin's disease.

Authors:  C Kretschmer; D B Jones; K Morrison; C Schlüter; W Feist; A J Ulmer; J Arnoldi; J Matthes; T Diamantstein; H D Flad
Journal:  Am J Pathol       Date:  1990-08       Impact factor: 4.307

4.  B7-H1 (PD-L1, CD274) suppresses host immunity in T-cell lymphoproliferative disorders.

Authors:  Ryan A Wilcox; Andrew L Feldman; David A Wada; Zhi-Zhang Yang; Nneka I Comfere; Haidong Dong; Eugene D Kwon; Anne J Novak; Svetomir N Markovic; Mark R Pittelkow; Thomas E Witzig; Stephen M Ansell
Journal:  Blood       Date:  2009-07-13       Impact factor: 22.113

5.  Immunohistochemical evidence of a role for transforming growth factor beta in the pathogenesis of nodular sclerosing Hodgkin's disease.

Authors:  M E Kadin; B A Agnarsson; L R Ellingsworth; S R Newcom
Journal:  Am J Pathol       Date:  1990-06       Impact factor: 4.307

6.  Immunocytochemical localization of secreted transforming growth factor-beta 1 to the advancing edges of primary tumors and to lymph node metastases of human mammary carcinoma.

Authors:  B I Dalal; P A Keown; A H Greenberg
Journal:  Am J Pathol       Date:  1993-08       Impact factor: 4.307

7.  Loss of receptors for transforming growth factor beta in human T-cell malignancies.

Authors:  M E Kadin; M W Cavaille-Coll; R Gertz; J Massagué; S Cheifetz; D George
Journal:  Proc Natl Acad Sci U S A       Date:  1994-06-21       Impact factor: 11.205

8.  The anaplastic lymphoma kinase controls cell shape and growth of anaplastic large cell lymphoma through Cdc42 activation.

Authors:  Chiara Ambrogio; Claudia Voena; Andrea D Manazza; Cinzia Martinengo; Carlotta Costa; Tomas Kirchhausen; Emilio Hirsch; Giorgio Inghirami; Roberto Chiarle
Journal:  Cancer Res       Date:  2008-11-01       Impact factor: 12.701

9.  Neutralizing antibodies against transforming growth factor beta potentiate the proliferation of Ki-1 positive lymphoma cells. Further evidence for negative autocrine regulation by transforming growth factor beta.

Authors:  S R Newcom; K K Tagra; M E Kadin
Journal:  Am J Pathol       Date:  1992-03       Impact factor: 4.307

Review 10.  The Dynamic Roles of TGF-β Signalling in EBV-Associated Cancers.

Authors:  Sharmila Velapasamy; Christopher W Dawson; Lawrence S Young; Ian C Paterson; Lee Fah Yap
Journal:  Cancers (Basel)       Date:  2018-07-27       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.